Back
Denali Therapeutics 10K Form
Sell
43
DNLI
Denali Therapeutics
Last Price:
28.21
Seasonality Move:
20.85%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-08-07 | 10Q | DNLI/Denali Therapeutics Quarterly |
2020-05-07 | 10Q | DNLI/Denali Therapeutics Quarterly |
2020-02-27 | 10K | DNLI/Denali Therapeutics Annual |
2019-11-06 | 10Q | DNLI/Denali Therapeutics Quarterly |
2019-08-06 | 10Q | DNLI/Denali Therapeutics Quarterly |
2019-05-08 | 10Q | DNLI/Denali Therapeutics Quarterly |
Receive DNLI News And Ratings
See the #1 stock for the next 7 days that we like better than DNLI
DNLI Financial Statistics
Sales & Book Value
Annual Sales: | $330.53M |
---|---|
Cash Flow: | $-96.01M |
Price / Cash Flow: | 0 |
Annual Sales: | $9.69 |
Price / Book: | 3 |
Profitability
EPS (TTM): | -2.85000 |
---|---|
Net Income (TTM): | $-419.65M |
Gross Margin: | -- |
Return on Equity: | 0% |
Return on Assets: | 0% |
Denali Therapeutics Earnings Forecast
Key Denali Therapeutics Financial Ratios
- The Research & Development expenses have been 128.24% of Revenue.
- The Net Earning history of DNLI is -43.94% of Total Revenues.
- Per Share Earnings over the last 9 years have been positive in 4 years.
Denali Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | DNLI |
CUSIP: | 24823R |
Website: | denalitherapeutics.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
DNLI Technical Analysis vs Fundamental Analysis
Sell
43
Denali Therapeutics (DNLI)
is a Sell
Is Denali Therapeutics a Buy or a Sell?
-
Denali Therapeutics stock is rated a Sell
The current Denali Therapeutics [DNLI] share price is $29.03. The Score for DNLI is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.